BISHOP JOHN L
Known title: DirectorCIK: 0001189846
Associated companies
Transaction History
| VCYT | ▲ Buy | Option Exercise | 10,000 | $64K | 7/18/2023 | View on chart |
| VCYT | ▼ Sell | Open Market | 10,000 | $305K | 7/18/2023 | View on chart |
| VCYT | ▼ Sell | Open Market | 10,000 | $300K | 7/17/2023 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 10,000 | $64K | 7/17/2023 | View on chart |
| VCYT | ▲ Buy | Grant | 9,674 | $0 | 6/9/2023 | View on chart |
| VCYT | ▲ Buy | Grant | 14,731 | $0 | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.